Table 1.
Geometric mean fold increase in serum anti‐alpha toxin neutralising levels over baseline
| Days | Placebo (n = 7) | 225 mg (n = 3) | 750 mg (n = 3) | 2250 mg (n = 8) | 5000 mg (n = 12) |
|---|---|---|---|---|---|
| 1 (pre‐infusion) | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
| 1 (end of infusion) | 1.3 | 8.1 | 34.7 | 179.4 | 240.5 |
| 1 (8 h postinfusion) | 1.3 | 7.1 | 30.6 | 164.3 | 230.9 |
| 2 | 1.1 | 6.2 | 29.1 | 156.7 | 193.9 |
| 4 | 1.1 | 4.7 | 20.5 | 127.2 | 147.7 |
| 6 | 1.0 | 4.3 | 20.1 | 106.9 | 138.1 |
| 8 | 1.1 | 4.2 | 19.0 | 97.9 | 126.6 |
| 15 | 1.1 | 4.2 | 16.6 | 85.0 | 115.7 |
| 22 | 1.0 | 3.9 | 18.3 | 67.4 | 104.8 |
| 31 | 1.1 | 3.9 | 15.2 | 70.1 | 96.4 |
| 61 | 1.1 | 3.1 | 13.4 | 52.7 | 81.1 |
| 91 | 1.1 | 2.6 | 9.6 | 50.2 | 69.5 |
| 121 | 1.0 | 2.3 | 8.9 | 35.5 | 54.5 |
| 151 | 0.9 | 2.2 | 6.7 | 28.8 | 40.9 |
| 211 | 0.9 | 2.1 | 6.1 | 18.5 | 21.0 |
| 271 | 1.0 | 1.5 | 4.1 | 11.3 | 16.5 |
| 361 | 1.3 | 1.3 | 3.0 | 6.9 | 9.7 |